Currently, there are 496.34M common shares owned by the public and among those 477.84M shares have been available to trade.
The company’s stock has a 5-day price change of -3.85% and -18.90% over the past three months. DKNG shares are trading -9.33% year to date (YTD), with the 12-month market performance down to -6.20% lower. It has a 12-month low price of $28.69 and touched a high of $53.61 over the same period. DKNG has an average intraday trading volume of 10.95 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.77%, -3.60%, and -12.41% respectively.
Institutional ownership of DraftKings Inc (NASDAQ: DKNG) shares accounts for 83.13% of the company’s 496.34M shares outstanding.
It has a market capitalization of $30.00B and a beta (3y monthly) value of 1.63. The earnings-per-share (ttm) stands at -$0.82. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.50% over the week and 2.60% over the month.
Analysts forecast that DraftKings Inc (DKNG) will achieve an EPS of 0.32 for the current quarter, 0.05 for the next quarter and 2.08 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.23 while analysts give the company a high EPS estimate of 0.23. Comparatively, EPS for the current quarter was 0.22 a year ago. Earnings per share for the fiscal year are expected to increase by 133.56%, and 309.73% over the next financial year.
Looking at the support for the DKNG, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on April 22, 2025, with the firm’s price target at $64-$52. Susquehanna coverage for the DraftKings Inc (DKNG) stock in a research note released on January 08, 2025 offered a Positive rating with a price target of $54. Mizuho was of a view on October 18, 2024 that the stock is Outperform, while Susquehanna gave the stock Positive rating on October 07, 2024, issuing a price target of $48- $50. Exane BNP Paribas on their part issued Neutral rating on September 10, 2024.
